Multiple system atrophy: An update
Identifieur interne : 000504 ( Istex/Curation ); précédent : 000503; suivant : 000505Multiple system atrophy: An update
Auteurs : Gregor K. Wenning [Autriche] ; Felix Geser [Autriche] ; Michaela Stampfer-Kountchev [Autriche] ; François Tison [Autriche]Source :
- Movement Disorders [ 0885-3185 ] ; 2003-09.
English descriptors
- KwdEn :
Abstract
Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder that usually manifests in the early sixth decade of life and progresses relentlessly with a mean survival of 9 years. Clinically, MSA is dominated by autonomic/urogenital failure, which may be associated with either levodopa (L‐dopa) ‐unresponsive parkinsonism in 80% of cases (MSA‐P subtype) or with cerebellar ataxia in 20% of cases (MSA‐C subtype). Pathologically, MSA is characterized by a neuronal multisystem degeneration and abnormal glial cytoplasmic inclusions containing α‐synuclein aggregates. Pharmacological treatment of motor features is disappointing except for a transient L‐dopa response in a minority of MSA‐P patients. In contrast, autonomic and urogenital features of MSA should be identified early on, because they can be treated effectively in many instances. Neuroprotective strategies are presently unavailable, however, two multicentre European trials have been launched to evaluate the effects of riluzole and human recombinant growth hormone on disease progression in MSA. Clearly, further randomised, controlled trials are required to identify effective symptomatic or neuroprotective agents in MSA. Several in vivo models have become available to allow a careful preselection of candidate agents. Several research groups have been formed in Europe (EMSA‐SG, NNIPPS) and United States (NAMSA‐SG), providing a framework for coordinated trial activity in MSA. © 2003 Movement Disorder Society
Url:
DOI: 10.1002/mds.10561
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000504
Links to Exploration step
ISTEX:E4A65AD7BF3DD5CB1D2BDC0A82AF58121D1F120FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Multiple system atrophy: An update</title><author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University Hospital, Innsbruck</wicri:regionArea></affiliation></author><author><name sortKey="Geser, Felix" sort="Geser, Felix" uniqKey="Geser F" first="Felix" last="Geser">Felix Geser</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University Hospital, Innsbruck</wicri:regionArea></affiliation></author><author><name sortKey="Stampfer Ountchev, Michaela" sort="Stampfer Ountchev, Michaela" uniqKey="Stampfer Ountchev M" first="Michaela" last="Stampfer-Kountchev">Michaela Stampfer-Kountchev</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University Hospital, Innsbruck</wicri:regionArea></affiliation></author><author><name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="François" last="Tison">François Tison</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University Hospital, Innsbruck</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E4A65AD7BF3DD5CB1D2BDC0A82AF58121D1F120F</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1002/mds.10561</idno><idno type="url">https://api.istex.fr/document/E4A65AD7BF3DD5CB1D2BDC0A82AF58121D1F120F/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000504</idno><idno type="wicri:Area/Istex/Curation">000504</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Multiple system atrophy: An update</title><author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University Hospital, Innsbruck</wicri:regionArea></affiliation></author><author><name sortKey="Geser, Felix" sort="Geser, Felix" uniqKey="Geser F" first="Felix" last="Geser">Felix Geser</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University Hospital, Innsbruck</wicri:regionArea></affiliation></author><author><name sortKey="Stampfer Ountchev, Michaela" sort="Stampfer Ountchev, Michaela" uniqKey="Stampfer Ountchev M" first="Michaela" last="Stampfer-Kountchev">Michaela Stampfer-Kountchev</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University Hospital, Innsbruck</wicri:regionArea></affiliation></author><author><name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="François" last="Tison">François Tison</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University Hospital, Innsbruck</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2003-09">2003-09</date><biblScope unit="vol">18</biblScope><biblScope unit="issue">S6</biblScope><biblScope unit="supplement">6</biblScope><biblScope unit="page" from="34">34</biblScope><biblScope unit="page" to="42">42</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">E4A65AD7BF3DD5CB1D2BDC0A82AF58121D1F120F</idno><idno type="DOI">10.1002/mds.10561</idno><idno type="ArticleID">MDS10561</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>glia</term><term>multiple system atrophy</term><term>riluzole</term><term>treatment</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder that usually manifests in the early sixth decade of life and progresses relentlessly with a mean survival of 9 years. Clinically, MSA is dominated by autonomic/urogenital failure, which may be associated with either levodopa (L‐dopa) ‐unresponsive parkinsonism in 80% of cases (MSA‐P subtype) or with cerebellar ataxia in 20% of cases (MSA‐C subtype). Pathologically, MSA is characterized by a neuronal multisystem degeneration and abnormal glial cytoplasmic inclusions containing α‐synuclein aggregates. Pharmacological treatment of motor features is disappointing except for a transient L‐dopa response in a minority of MSA‐P patients. In contrast, autonomic and urogenital features of MSA should be identified early on, because they can be treated effectively in many instances. Neuroprotective strategies are presently unavailable, however, two multicentre European trials have been launched to evaluate the effects of riluzole and human recombinant growth hormone on disease progression in MSA. Clearly, further randomised, controlled trials are required to identify effective symptomatic or neuroprotective agents in MSA. Several in vivo models have become available to allow a careful preselection of candidate agents. Several research groups have been formed in Europe (EMSA‐SG, NNIPPS) and United States (NAMSA‐SG), providing a framework for coordinated trial activity in MSA. © 2003 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000504 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000504 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:E4A65AD7BF3DD5CB1D2BDC0A82AF58121D1F120F
|texte= Multiple system atrophy: An update
}}
| This area was generated with Dilib version V0.6.23. |  |